Solana Co

Listed Company
HSDTCIK 0001610853NasdaqNon-AcceleratedSmaller ReportingFinance ServicesDelawareFY ends Dec 31
Period
FY 2025
Revenue
$6.02M
Net Income
$-40.89M
Total Assets
$303.93M
Equity
$300.91M
Shares Out
55.03M
Op. Cash Flow
$-16.51M

Business

Solana Co is a neurotechnology company that develops, licenses and acquires non‑implantable technologies for neurological wellness focused on reducing symptoms of neurological disease or trauma. Its main product is the Portable Neuromodulation Stimulator (PoNS®) and the associated PoNS Therapy, a controller and mouthpiece system delivering translingual electrical stimulation used as an adjunct to supervised therapeutic exercise to treat gait and balance deficits. Key business divisions include clinical research and regulatory affairs, product development and manufacturing, and commercialization and distribution. The company markets PoNS in the U.S., Canada and Australia and distributes through authorized clinics, telehealth/e‑commerce platforms and strategic distribution partnerships, including federal healthcare channels.

Summary from filing dated 2025-03-25

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts
ConceptTrend
FY 2025
2025-12-31
FY 2024
2024-12-31
FY 2023
2023-12-31
FY 2022
2022-12-31
FY 2021
2021-12-31
Staking revenue5
Product sales and other revenue548,000520,000605,000778,000493,000
Total revenue6520,000644,000787,000522,000
Cost of revenue500,000582,000
Gross profit (loss)6−62,00061,000324,000224,000
Selling, general and administrative expenses231091112
Research and development expenses44346
Unrealized loss on digital assets and digital assets receivable209
Realized loss on digital assets12
Unrealized loss on digital assets fund investment2
Realized gain on digital asset derivatives−316,000
Total operating expenses24914121618
Loss from operations−244−14−12−16−18
Interest expense, net−635,000−17,000257,000−834,000
Foreign exchange gain (loss) and other income785,000−803,000275,000−756,00010,000
Change in fair value of derivative liability938333
Loss on derivative liability−540
Financing costs−195
Nonoperating income, net20324110,000
Loss before provision for income taxes−41−12−9−14−18
Provision for income taxes00000
Net loss−41−12−9−14−18
Foreign currency translation adjustments−594,0001−285,000737,000−26,000
Comprehensive loss−41−11−9−13−18
Basic (in dollars per share)−1.85−3,282−14.56−52.13−7.38
Diluted (in dollars per share)−1.85−3,282−14.56−52.13−7.38
Basic (in shares)223,577607,890269,9292
Diluted (in shares)223,577607,890269,9292

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro